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Abstract. Background/Aim: Hypoxia can affect chemo -
therapeutic drug efficacy in cancer patients, yet related in
vitro assays in oxygen-rich environment remain the norm.
Such levels are well beyond normoxic/hypoxic levels typically
experienced by normal tissues/tumor masses. The present
study evaluated how artesunate anti-tumor efficacy is
modulated by oxygen availability in HeLa cells and its
implications for future in vitro analyses. Materials and
Methods: Real-time cell analysis was employed to evaluate
HeLa cell toxicity to artesunate at 21%, 4% or 1% oxygen.
Cell count analysis was performed to validate real-time data.
Results: An increase in artesunate efficacy was observed
when oxygen concentration was reduced from atmospheric
levels down to in vivo-relevant levels. Conclusion: Artesunate
is more potent than originally reported using standard
oxygen conditions during in vitro studies. The inclusion of
this long overlooked variable as standard in future in vitro
analysis procedures is warranted. 
Chemotherapy, radiation and surgery are the standard
methods of cancer treatment today. However, multidrug
resistance is a reoccurring drawback with chemotherapy and
is displayed by many patients (1). In addition, the majority of
chemotherapeutics have many side effects that are associated
with high toxicity levels. Therefore, the search is ongoing for
novel compounds with potential for more effective
chemotherapy. 
Tissue hypoxia is defined by clinicians as a decrease in
oxygen availability below critical levels, which compromises
the function of cells, tissues or organs (2). This critical value
has been identified in a previous clinical study as pO2 of <10
mm Hg or <1.3%(v/v) oxygen (3). Hypoxia often develops
in tumors due to poor blood supply and inadequate oxygen
diffusion. More than 50% of solid tumors exhibit areas of
hypoxia throughout the tumor mass, with areas of anoxia (no
oxygen availability) also occurring (4). Tumor tissue derived
from cervical, prostate, breast, head and neck, brain and soft
tissue cancers displayed oxygen levels varying from 0.3-
2.4% (2-18 mm Hg) (5). Based on this evidence, an oxygen
concentration of 1% (v/v) was employed in the present study
to mimic hypoxia in vivo. Tumor hypoxia is associated with
poor prognosis in cancer patients by driving malignant
progression. This is achieved through changes in gene
expression of growth factors and survival proteins to enable
tumor cells to withstand nutrient deprivation and grow in an
unregulated manner (2). Apoptosis, cell-cycle arrest,
angiogenesis, glycolysis and pH regulation are thought to be
regulated by hypoxia-induced genes, usually under the
control of hypoxia inducible factor 1 (HIF-1) (6). Hypoxia
has also been implicated in conferring resistance to
chemotherapy and radiotherapy. Tumor cell oxygenation was
first shown to be a key factor in efficacy of irradiation
treatment of cancer over 50 years ago (7). Furthermore many
chemotherapeutic drugs are dependent on oxygenation of the
tumor mass for optimal efficacy. Tumor cells in normoxic
conditions were shown to be more sensitive to melphalan, a
DNA alkylating chemotherapeutic agent, when compared to
cells under hypoxic conditions (8, 9). Hypoxia dramatically
alters cell cycle distribution with the majority of cells in
G1/S phase arrest (10). Consequently, chemotherapeutics that
target DNA may be susceptible to hypoxia-induced
resistance due to a substantial reduction in cell division and
DNA replication. Moreover artemisinin was shown to be
30% more effective in an oxygen rich environment (21% O2,
or 152 mm Hg) when compared to a low oxygen
environment (1%, 7.6 mm Hg) in treatment of P. falciparum
strain of malaria.
7055
Correspondence to: James Murphy, Mitochondrial Biology &
Radiation Research Centre, Dept. Life Sciences, Institute of
Technology Sligo, Ash Lane, Sligo, Ireland. Tel: +353 719155239,
Fax: +353 719144500, e-mail: murphy.james@itsligo.ie
Key Words: Oxygen-rich enviroment, artesunate, HeLa cells, in vitro
study, hypoxia.
ANTICANCER RESEARCH 34: 7055-7060 (2014)
In Vitro Oxygen Availability Modulates the 
Effect of Artesunate on HeLa cells 
JAMES MURRAY1, SANDRA GANNON2, SARAH RAWE3 and JAMES E. J. MURPHY1
1Mitochondrial Biology & Radiation Research Centre, Department of Life Sciences, 
Institute of Technology Sligo, Sligo, Ireland; 
2MSA Laboratory, Focas Institute, and 3School of Chemical and Pharmaceutical Sciences, 
Dublin Institute of Technology, Dublin, Ireland
0250-7005/2014 $2.00+.40
Despite evidence suggesting that hypoxia is crucial in
chemotherapy outcome, almost all in vitro evaluation of
novel compounds is performed in standard oxygen-rich
environments (20-21% O2 or 152-160 mm Hg) (11-13). This
is markedly different from the normoxic oxygen levels
typical of normal cells in vivo or indeed from the hypoxic or
anoxic regions of a typical tumor mass. Several studies have
investigated tissue oxygenation levels in vivo both in the case
of tumor and non-tumor tissue (5, 14). The oxygen
concentration in many non-tumor tissues in vivo is
approximately 4-5% (38 mmHg) (normoxia) and is
maintained within a narrow optimal range. This range
however varies between tissue types. For example lung tissue
oxygenation can be up to 14% (30-38 mm Hg) whereas liver
and bone cartilage is usually within a 2-8% (15-61 mm Hg)
range (15). Tumor tissue derived from cervical cancer,
prostate cancer, breast cancer, head and neck carcinoma,
glioblastoma and soft tissue carcinoma displayed oxygen
levels varying from 0.3-2.4% (2-18 mmHg) (5). 
Artemisinin is a sequiterpene lactone containing a 1,2,4
trioxane ring within its chemical structure. Artemisinin was
first isolated from the Chinese herb quinghaosu (Artemisia
annua or annual wormwood) in 1972 (16). Artemisinin has
been used for centuries as an effective Chinese medicine for
treatment of fevers, P. falciparum and P. vivax malaria strains.
Naturally-occurring artemisinin has low solubility in oil and
water prompting the production and use of several semi-
synthetic derivatives such as Artemether, Arteether and
Artesunate (ART). All are effective against multidrug-resistant
plasmodium strains of malaria. Interestingly, artemisinin and
semi-synthetic derivatives have also been shown to have potent
anticancer properties both in vitro and in vivo (17-20). It was
reported by Nakase et al. (2008) that artemisinin and its
derivatives induce apoptosis in -the very aggressive- Kaposi's
sarcoma cells. Treatment of human vein endothelial cells
(HUVEC) with concentrations above 2.5 μM resulted in cell
growth inhibition, which increased with drug concentration.
Fifty-five different cell lines from the Developmental
Therapeutics Program of the National Cancer Institute NCI
were treated with ART, resulting in growth inhibition of a
multitude of cancer cell lines including leukaemia, breast,
colon, ovarian, prostate, central nervous system (CNS),
melanoma and lung cancer (22).) Furthermore ART was
effective against 15 out of 16 neuroblastoma cell lines tested
in a recent investigation (23). A major advantage of artesunate
is the lack of cross resistance. ART and similar derivatives are
valuable in the treatment of multidrug-resistant strains of
malaria worldwide. Cancer therapy is also frequently adversely
affected by the development of resistance by tumors. This has
prompted researchers to determine whether multidrug-resistant
tumors could be effectively treated with ART. ART was shown
to be effective against multidrug-resistant small cell lung
cancer (SCLC) cell line H69VP when preloading of cells with
transferrin was performed (24). ART was shown to be just as
potent against multidrug-resistant cell lines that over-express
MDR1/P glycoprotein, MRP1 and BCRP (25). Additionally,
hydroxyurea-resistant CEM/HUR90 cells and methotrexate-
resistant CEM/MTX1500LV cells also exhibited no cross
resistance to ART. On the evidence of such research, artesunate
and similar derivatives could be utilised for treatment of
cancers displaying inherent multidrug resistance. However,
cancer cells with up-regulated expression of antioxidants such
as glutathione transferase have shown resistance to ART by
reversal of the ROS-induced damage (25).
In the present study, a novel real-time cell analysis
software was employed to investigate HeLa cell sensitivity
to ART in varying oxygen environments of atmospheric
oxygen, normoxia and hypoxia. This impedance-based,
label-free assay was chosen ahead of alternative cellular
assays such as MTT due to a potential effect of varying
oxygen on cellular metabolism (26). The xCELLigence
System measures electrical impedance across micro-
electrodes integrated on the bottom of cell culture plates.
Impedance data are automatically converted to Cell Index
(CI) values by the software. Cell index is defined as a
relative change in electrical impedance created by attached
cells, which is indicative of cell number, cellular adhesion,
cell proliferation, cell size and morphology. As cells detach
and die the cell-covered area reduces and CI values decrease.
Thus xCELLigence system offers a much more informative
and dynamic cell analysis in real time when compared to
static endpoint analysis at selected time points.
Materials and Methods
Cell culture. HeLa cervical cancer cells (European Collection of
Cell Cultures) were cultured in Dulbecco’s Modified Essential
Medium (DMEM F12) (Sigma Aldrich, Dorset, UK) supplemented
with 5% Foetal Bovine Serum (Sigma Aldrich) and 1% penicillin
/streptomycin (Sigma Aldrich) and 1% L-Glutamine (Sigma
Aldrich). Cells were maintained at 37˚C, 95% humidity, 5% (v/v)
CO2. Cells were also maintained at Oxygen concentrations of either
1% (v/v) (7.6 mmHg), 4% (v/v) (30 mmHg) or 21% (v/v) (160 mm
Hg) for a minimum of 24 h before any experiment was commenced
and until analysis was completed. 
Preparation and addition of artesunate. ART was kindly provided
by Dr Sarah Rawe, School of Chemical and Pharmaceutical
Sciences, Dublin Institute of Technology. ART was dissolved in
dimethyl sulfoxide (DMSO) and further diluted in complete DMEM
F12 medium, such that when added to cells, the final concentration
of DMSO in all cells was maintained at 0.1% (v/v).
Real-time cell analysis. E-plates (ACEA Biosciences, San Diego,
CA, USA) were seeded with 4-5×103 HeLa cells per well, 24 h
before artesunate exposure. E-plates were placed within the cradle
of an xCELLigence DP Real Time Cell Analyser that remained
inside the incubator for the duration of the experiment. 24 h post-
seeding, half the medium was removed from each well and replaced
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with an equal volume of either fresh complete medium, 0.2% (v/v)
DMSO in fresh complete medium, 0.2% (v/v) DMSO + 20 μM ART
in fresh complete medium or 0.2% (v/v) DMSO + 100 μM ART in
fresh complete medium. Cell growth data was captured every 15
min for the duration of the experiment, beginning 24 h before drug
addition and continuing for a minimum of 48 h post drug addition
and is displayed by the built-in software as “Cell Index”.
Cell count analysis. HeLa cells were seeded on a 6-well plate
(Sarstedt, Nümbrecht, Germany) at 100,000-120,000 cells per well
(equal density to real time cell analysis). 24 h post-seeding, half the
medium was removed from each well and replaced with an equal
volume of either fresh complete medium, 0.2% (v/v) DMSO in fresh
complete medium, 0.2% (v/v) DMSO + 20 μM ART in fresh
complete medium or 0.2% (v/v) DMSO + 100 μM ART in fresh
complete medium. Cells were harvested and counted 0, 24 or 48 h
later using a Z2 Particle Analyser (Beckman Coulter, Miami, FL,
USA). Cell counts are expressed as a percentage of control. 
Results
In vitro real-time cell analysis was performed at three different
oxygen concentrations, 21% (atmospheric), 4% (normoxia) and
1% (hypoxia). Cells were either exposed to no change (DMEM
only), vehicle-only, 10 μM artesunate or 50 μM artesunate
(Figure 1). In atmospheric oxygen conditions, it could be
observed that 10 μM artesunate began to inhibit cell growth 24
h post-treatment, whereas 50 μM artesunate caused HeLa cell
death as early as 12 h after drug treatment. Interestingly, when
oxygen availability was reduced to that of normoxic conditions,
an increase in artesunate efficacy was observed. This was
particularly evident in cells exposed to 10 μM artesunate,
where growth inhibition was observed 12 h post-drug addition
and a substantial reduction was observed 48 h post-addition. In
normoxia, 50 μM artesunate resulted in HeLa cell cytotoxicity
after 10 h and was fatal to all cells by 48 h. 
When artesunate was analysed in hypoxic conditions, a
similar increase in HeLa cell sensitivity to the drug was
observed; 10μM artesunate caused considerable cell growth
inhibition when compared to sham exposed control.
Furthermore 50μM artesunate treatment induced cell
cytotoxicity after just 10 h, resulting in almost complete cell
death after 48 h. 
Cell survival analysis was performed by counting cells in
a Beckman Coulter Z2 particle analyser. Experiments were
performed at three different oxygen concentrations, 21%
(atmospheric), 4% (normoxia) and 1% (hypoxia). Cells were
either exposed to no change, 0 μM, 10 μM or 50 μM
artesunate 24 h after seeding and cells were counted at 0, 24
or 48 h post exposure. All data are expressed as a percentage
of cell numbers at 0 h post-artesunate exposure (Figure 2).
Artesunate reduced cell number in a dose-dependent manner
at all 3 oxygen environments. However, an enhanced cell
sensitivity at lower oxygen concentrations was evident,
particularly at the dose of 10 μM.
Discussion
Hypoxic regions are typically present within solid tumor
masses due to inadequate blood supply. Hypoxia is
associated with a more aggressive tumor phenotype, which
often displays resistance to chemotherapy and radiotherapy
(3, 4, 7, 27, 28). Moreover chemotherapeutic drugs are often
dependent on oxygenation of the tumor mass for optimal
efficacy (8, 9). However, despite the evidence that tissue
oxygenation is important in response to chemotherapy,
almost all in vitro cytotoxic assays to date have been
performed in standard oxygen rich environment of 21% (v/v)
or 160 mmHg. This is markedly different to tissue oxygen
levels in vivo with many tissues of the body having 4%
oxygenation (normoxia). This range however varies between
tissue types. Lung tissue oxygenation can be up to 14% (14),
whereas liver and bone cartilage is usually within the 2-8%
oxygen range (15). Conversely tumor tissue derived from
cervical cancer, prostate cancer, breast cancer, head and neck
carcinoma, glioblastoma and soft tissue carcinoma displayed
oxygen levels varying from 0.3-2.4% (2-18 mmHg) (5). 
In the present study novel real-time cell analysis (RTCA)
software was employed to investigate the effect of oxygen in
potentiating cellular response to anticancer agents. This new
impedance based assay is non-invasive and label-free,
providing dynamic detection of changes in cell proliferation,
cell number, cellular adhesion, cell size and morphology in
real time rather than at selected end-points on a bar graph.
The resulting data are automatically converted to cell index
(CI) by the software (29, 30). As cells detach and die (due
to cytotoxic agent) the surface area covered by cells is
reduced and CI values decrease. For this study it was
necessary to choose a well-studied drug with anticancer
activity. Artesunate (ART) is a semi-synthetic derivative of
artemisinin with anti-malarial and anti-cancer activity and
was chosen for this analysis (22). HeLa cervical cancer cells
were employed as a tumor cell line model and are known to
be sensitive to artesunate (31, 32) though notably when
analyzed in oxygen-rich conditions. In this study we
demonstrated that ART potency against HeLa cervical cancer
cells is enhanced as oxygen concentration is varied from
atmospheric levels to in vivo-relevant normoxia and hypoxia.
In atmospheric oxygen conditions (Figure 1), it could be
observed that ART began to inhibit cell growth in a dose-
dependent manner with 50 μM ART resulting in HeLa cell
death as early as 12 h post-drug treatment. However, when
oxygen availability was reduced to in vivo body relevant
oxygen concentrations of 4% (normoxia) and 1% (hypoxia),
a significant increase in ART efficacy was observed. This
was particularly evident in cells exposed to 10 μM ART,
where growth inhibition was observed as early as 10 h post-
treatment. Furthermore, 50 μM artesunate resulted in HeLa
cell cytotoxicity after 10 h and was fatal to all cells by 48 h.
Murray et al: Oxygen Availability Modulates Artesunate
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When ART was analyzed in hypoxic conditions, a similar
increase in HeLa cell sensitivity to the drug was observed
compared to that of atmospheric oxygen. This is significant,
since many aggressive malignant tumors exhibit areas of
hypoxic tissue (33). 
Therefore artesunate, and indeed many other chemothera-
peutic agents assessed at atmospheric oxygen, may be more
potent against cancer cells in vivo than originally thought.
Cell count analysis was also performed (Figure 2) to
corroborate with RTCA as this is a relatively new technique.
By investigating cell numbers at 0, 24 and 48 h post-drug
exposure, a similar dose-dependent response of HeLa to
Artesunate can be observed. A significant increase in drug
ANTICANCER RESEARCH 34: 7055-7060 (2014)
7058
Figure 1. Real-time cell analysis of HeLa cells in (A) 21% oxygen, (B)
4% oxygen or (C) 1% oxygen conditions. HeLa cells seeded at 5×103
cells/well, treated with drugs after 24 h growth and monitored using
real-time cell analysis until experiment end at 72 h. Cell viability is
plotted as cell index (CI) on y axis. Each real time experiment was
performed 3 times.
Figure 2. HeLa survival assay: HeLa cells maintained in either (A) 21%
oxygen, (B) 4% oxygen or (C) 1% oxygen conditions. HeLa cells seeded
in 6-well plates were counted to measure relative cell survival and are
expressed as a percentage of cell numbers at time zero drug addition.
All data is representative of triplicate experiments (±SD). Differences
between treated/exposed and sham exposed/control cell populations were
analyzed using one-way ANOVA, with Tukey post hoc test using p<0.05
as the criterion for significance (*p≤0.05 , **p≤0.01, ***p≤0.001).
efficacy can be observed in 10 μM artesunate when oxygen
availability is lowered below 4% oxygen, further supporting
real-time data.
Treatment of HeLa cervical cancer cells with artesunate at
varying oxygen conditions of atmospheric, normoxia and
hypoxia revealed an increase in ART efficacy when oxygen
levels were lowered to in vivo levels. ART is even more
potent than originally reported during in vitro studies.
Additionally, static end-point assays such as MTT, which
rely on mitochondria, may be far more active at atmospheric
conditions, than would otherwise be at normoxia.
Consequently there is a need to factor this long overlooked
variable as standard procedure for future in vitro analyses.
Oxygen concentration is a parameter that can no longer be
overlooked for future design of in vitro analyses. 
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